Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoablation versus bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer
2022-502221-18-00Phase 4Authorised
- Sponsor
- Aarhus University
- Start
- Dec 2024
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of mitomycin c and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Aarhus University. Primary endpoint: Two-year recurrence-free survival. Planned start Dec 2024; status: authorised.
02
Drugs
mitomycin cbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2022-502221-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502221-18-00.